Cargando…

Epigenetic Drugs for Multiple Sclerosis

There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the development of multiple sclerosis (MS). Advances in epigenetics have given rise to a new class of drugs, epigenetic drugs. Although many classes of epigenetic drugs are being investigated, a...

Descripción completa

Detalles Bibliográficos
Autor principal:	Peedicayil, Jacob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4787283/ https://www.ncbi.nlm.nih.gov/pubmed/26813117 http://dx.doi.org/10.2174/1570159X13666150211001600

Ejemplares similares

The Potential Role of Epigenetic Drugs in the Treatment of Anxiety Disorders
por: Peedicayil, Jacob
Publicado: (2020)

Epigenetic management of major psychosis
por: Peedicayil, Jacob
Publicado: (2011)

Epigenetics as a link between psychosocial factors and mental disorders
por: Peedicayil, Jacob
Publicado: (2015)

Identification of Biomarkers in Neuropsychiatric Disorders Based on Systems Biology and Epigenetics
por: Peedicayil, Jacob
Publicado: (2019)

The Role of Epigenetics in the Pathogenesis and Potential Treatment of  Attention Deficit Hyperactivity Disorder
por: Peedicayil, Jacob
Publicado: (2022)

Exposure to Enriched Environment May Act Epigenetically to Correct Defects due to Chronic Restraint Stress in Rats
por: Peedicayil, Jacob
Publicado: (2019)

Epigenetic control of ataxin‐1 in multiple sclerosis
por: Ma, Qin, et al.
Publicado: (2022)

Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review
por: Joseph, Silvia, et al.
Publicado: (2022)

DNA Methylation As an Epigenetic Mechanism in the Development of Multiple Sclerosis
por: Kiselev, I. S., et al.
Publicado: (2021)

The relevance of polycomb group proteins to the development of psychiatric disorders
por: Peedicayil, Jacob
Publicado: (2022)

Genome–Environment Interactions and Psychiatric Disorders
por: Peedicayil, Jacob
Publicado: (2023)

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation
por: Andlauer, Till F. M., et al.
Publicado: (2016)

Expression of IL-33 and its epigenetic regulation in multiple sclerosis
por: Zhang, Fanglin, et al.
Publicado: (2014)

Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis
por: Maltby, Vicki, et al.
Publicado: (2023)

Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis
por: Iannello, Andrea, et al.
Publicado: (2019)

Repurposing Histaminergic Drugs in Multiple Sclerosis
por: Amadio, Susanna, et al.
Publicado: (2022)

Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients
por: Maltby, Vicki E., et al.
Publicado: (2020)

Drug repurposing for neuroregeneration in multiple sclerosis
por: Küry, Patrick, et al.
Publicado: (2018)

Multiple sclerosis drug repurposing for neuroregeneration
por: Göttle, Peter, et al.
Publicado: (2023)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Xavier, Alexandre, et al.
Publicado: (2023)

Inhibition by tadalafil of contractility of isolated nonpregnant human myometrium
por: Sen, Sumalya, et al.
Publicado: (2016)

Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis
por: Ayuso, Teresa, et al.
Publicado: (2017)

Inhibition by Benidipine of Contractility of Isolated Proximal and Distal Caprine Ureter
por: Mathew, Sumith K, et al.
Publicado: (2017)

Gait Variability and Multiple Sclerosis
por: Socie, Michael J., et al.
Publicado: (2013)

Epigenetic clock indicates accelerated aging in glial cells of progressive multiple sclerosis patients
por: Kular, Lara, et al.
Publicado: (2022)

Integration of epigenetic and genetic profiles identifies multiple sclerosis disease-critical cell types and genes
por: Ma, Qin, et al.
Publicado: (2023)

Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
por: Wei, Weipeng, et al.
Publicado: (2021)

Genetic polymorphisms and epigenetic regulation of survivin encoding gene, BIRC5, in multiple sclerosis patients
por: Rahban, Dariush, et al.
Publicado: (2019)

Epigenetic Modifications in the Pathogenesis of Systemic Sclerosis
por: Yu, Jiangfan, et al.
Publicado: (2022)

The use of immune modulating drugs for the treatment of multiple sclerosis
por: Al-Khamis, Fahd A.
Publicado: (2016)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
por: Issa, Mark E., et al.
Publicado: (2017)

Epigenetic mechanisms shape the underlining expression regulatory mechanisms of the STAT3 in multiple sclerosis disease
por: Hosseini, Arezoo, et al.
Publicado: (2020)

Multiple sclerosis and drug discovery: A work of translation
por: ’t Hart, Bert A., et al.
Publicado: (2021)

Novel Drugs in a Pipeline for Progressive Multiple Sclerosis
por: Sapko, Klaudia, et al.
Publicado: (2022)

Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis
por: Dasari, Harika, et al.
Publicado: (2016)

A role for cathepsin Z in neuroinflammation provides mechanistic support for an epigenetic risk factor in multiple sclerosis
por: Allan, Euan R. O., et al.
Publicado: (2017)

Leg Spasticity and Ambulation in Multiple Sclerosis
por: Balantrapu, Swathi, et al.
Publicado: (2014)

Role of epigenetics-microRNA axis in drug resistance of multiple myeloma
por: Rastgoo, Nasrin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0rv0dfhgv3ar3oi77knor7bdto